{"paper_id": "978d74fe934b85559f21f8de5b5784424aec0b06", "metadata": {"title": "DEVELOPMENT OF VACCINES AND PASSIVE IMMUNOTHERAPY AGAINST SARS CORONAVIRUS USING MOUSE AND SCID-PBL/hu MOUSE MODELS", "authors": [{"first": "Masaji", "middle": [], "last": "Okada", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yuji", "middle": [], "last": "Takemoto", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yoshinobu", "middle": [], "last": "Okuno", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Satomi", "middle": [], "last": "Hashimoto", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yukari", "middle": [], "last": "Fukunaga", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Takao", "middle": [], "last": "Tanaka", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yoko", "middle": [], "last": "Kita", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Sechiko", "middle": [], "last": "Kuwayama", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yumiko", "middle": [], "last": "Muraki", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Noriko", "middle": [], "last": "Kanamaru", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Hiroko", "middle": [], "last": "Takai", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Chika", "middle": [], "last": "Okada", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yayoi", "middle": [], "last": "Sakaguchi", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Izumi", "middle": [], "last": "Furukawa", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Kyoko", "middle": [], "last": "Yamada", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Miwa", "middle": [], "last": "Izumiya", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Shigeto", "middle": [], "last": "Yoshida", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Makoto", "middle": [], "last": "Matsumoto", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Tetsuo", "middle": [], "last": "Kase", "suffix": "", "affiliation": {}, "email": ""}, {"first": "J", "middle": ["S M"], "last": "Peiris", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Daphne", "middle": ["E"], "last": "Demello", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Pei-Jer", "middle": [], "last": "Chen", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Naoki", "middle": [], "last": "Yamamoto", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yoshiyuki", "middle": [], "last": "Yoshinaka", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Tatsuji", "middle": [], "last": "Nomura", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Isao", "middle": [], "last": "Ishida", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Shigeru", "middle": [], "last": "Morikawa", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Masato", "middle": [], "last": "Tashiro", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Mitsunori", "middle": [], "last": "Sakatani", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Sachiko", "middle": ["Kyoko"], "last": "Yamada", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yumiko", "middle": [], "last": "Kuwayama", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Noriko", "middle": [], "last": "Muraki", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Hiroko", "middle": [], "last": "Kanamaru", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Chika", "middle": [], "last": "Takai", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yayoi", "middle": [], "last": "Okada", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Izumi", "middle": [], "last": "Sakaguchi", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Furukawa", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": "We have investigated novel vaccines strategies against severe acute respiratory syndrome (SARS) CoV infection using cDNA constructs encoding the structural antigens; spike (S), membrane (M), envelope (E), or nucleocapsid (N) protein, derived from SARS CoV (strain HKU39849, TW1, or FFM-1). As SARS-CoV is thought to infect the alveolar epithelial cell of the lung,in the present study, a type II alveolar epithelial cell clone, T7, was used to analyze the mechanism of CTL against SARS CoV membrane antigens. Mice On the other hand, we have developed SARS DNA vaccines that induce human neutralizing antibodies and human monoclonal antibodies against SARS CoV. Transgenic mice expressing SARS-CoV receptor (angiotensin converting enzyme 2) are also under development. These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines.", "cite_spans": [], "ref_spans": [], "section": "ABSTRACT"}, {"text": "The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of corona virus, SARS corona virus (SARS-CoV) more than 8400 patients in about 7 months in over 30 countries and caused more than 800 deaths. The deadly epidemic has had significant impacts on many health, social, economic and political aspects. SARS may resurge in the near future. However, no SARS vaccine is currently available for clinical use. Therefore, we have developed novel vaccine candidates against SARS CoV using cDNA constructs encoding the structural antigens; S, M, E, or N protein. In immunized mice, neutralizing antibodies against the virus and T-cell immunity against virus-infected-cells were studied, since these responses play important roles in protection against many virus infections. In particular, CD8 + CTL plays an important role in T cell immunity against virus infections and in the eradication of murine and human cancers. 4, 5 In the present study, a type II alveolar epithelial cell clone, T7, was used for activity (IFN-\u03b3 production by recombinant N protein or N protein-pulsed autologous B \u03b3 1,2,3 . SARS has infected ", "cite_spans": [{"start": 954, "end": 956, "text": "4,", "ref_id": "BIBREF4"}, {"start": 957, "end": 958, "text": "5", "ref_id": "BIBREF5"}], "ref_spans": [], "section": "INTRODUCTION"}, {"text": "analyzing precise mechanism of CTL against SARS-CoV membrane antigens, as the SARS-CoV infects alveolar epithelial cell in the lungs. 6 Furthermore, the SCID-PBL/hu model, which is capable of analyzing in vivo human immune response, was also used because it is a more relevant translational model for human cases. 4 These vaccines induce human immune responses (neutralizing antibody and CTL) specific for SARS CoV in human and should provide useful tool for development of protective vaccines.", "cite_spans": [{"start": 134, "end": 135, "text": "6", "ref_id": "BIBREF6"}, {"start": 314, "end": 315, "text": "4", "ref_id": "BIBREF4"}], "ref_spans": [], "section": "Augmentation of lymphocyte proliferation specific for SARS CoV antigens by"}, {"text": "Three SARS CoV strains HKU39849 1 , TW-1, and FFM-1 2 and their cDNAs were used. S, M, N, or E cDNA was transferred into pcDNA 3.1(+) vector and pcDNA 3.1(+)/vs-His Topo (QIAGEN K K, Tokyo, Japan). These genes were expressed in eukaryotic cells and Escherichia coli. pcDAN 3.1(+) vector, 50 \u03bcg each, containing SARS S, M, N, or E DNA was injected i.m. (M. tibia anterior) into C57BL/6 mice (female, 8 weeks, CLEA Japan Inc, Japan) and BALB/c mice (female, 8 weeks) three times, at an interval of 7 days. Neutralizing antibodies against SARS CoV in the serum from the mice immunized with SARS S, M, N, or E DNA vaccines were assayed using Vero-E6 cell. CTL activity against SARS-CoV was studied using human type II alveolar epithelial cells, T7, expressing SARS antigens. 6 PBL from healthy human volunteers were administered i.p. SCID-PBL/hu mice were constructed. 4 SARS DNA vaccines at 50 \u03bcg were injected i.m. into the SCID-PBL/hu mice. CTL activity of human CD8-positive lymphocytes in the spleen from SCID-PBL/hu was assessed using IFN-\u03b3 production and 51 Cr-release assay 4, 5 Human monoclonal antibodies were produced from B cell hybridoma using P3U1 myeloma cell and spleen cells from human immunoglobulin transchromosomic mice (KM mice). while another SARS DNA vaccine encoding N protein generated IFN-\u03b3-producing", "cite_spans": [{"start": 771, "end": 772, "text": "6", "ref_id": "BIBREF6"}, {"start": 865, "end": 866, "text": "4", "ref_id": "BIBREF4"}, {"start": 1078, "end": 1080, "text": "4,", "ref_id": "BIBREF4"}, {"start": 1081, "end": 1082, "text": "5", "ref_id": "BIBREF5"}], "ref_spans": [], "section": "MATERIALS AND METHODS"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "This study was supported by Grant-in-Aid for science and technology and Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, and Labour Science Research Grant from the Ministry of Health, Labour, and Welfare", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "It has been demonstrated that angiotensin-converting enzyme 2 (ACE2) is a functional receptor for the SARS CoV. 9 A transgenic mouse with human ACE-2 may be useful as an animal model of SARS. Furthermore, ACE-2 transgenic SCID mice should be useful as a human model for preclinical trial for SARS vaccines, for analyzing human immune responses against SARS infection in vivo. The effect of combination immunization with such SARS vaccines and nentralizing antibody-inducing DNA vaccines is now being studied", "authors": [{"first": "Sars", "middle": [], "last": "Dna", "suffix": ""}], "year": null, "venue": "DNA vaccines capable of inducing human neutralizing antibodies against SARS CoV have been established by our SCID-PBL/hu model", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "SARS study group. Coronavirus as a possible cause of severe acute", "authors": [{"first": "J", "middle": ["S"], "last": "Peiris", "suffix": ""}, {"first": "S", "middle": ["T"], "last": "Lai", "suffix": ""}, {"first": "L", "middle": ["L"], "last": "Poon", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Identification of a novel coronavirus in patients with severe acute 3", "authors": [{"first": "C", "middle": [], "last": "Drosten", "suffix": ""}, {"first": "S", "middle": [], "last": "Gunther", "suffix": ""}, {"first": "W", "middle": [], "last": "Preiser", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene", "authors": [{"first": "F", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "M", "middle": [], "last": "Abe", "suffix": ""}, {"first": "T", "middle": [], "last": "Akiyoshi", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Establishment and characterization of human", "authors": [{"first": "M", "middle": [], "last": "Okada", "suffix": ""}, {"first": "N", "middle": [], "last": "Yoshimura", "suffix": ""}, {"first": "T", "middle": [], "last": "Kaieda", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yamamura", "suffix": ""}, {"first": "T", "middle": [], "last": "Kishimoto", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Generation of an immortal differentiated lung type-II", "authors": [{"first": "", "middle": [], "last": "De", "suffix": ""}, {"first": "S", "middle": [], "last": "Mahmoud", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Padfield", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Hoffmann", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Effects of a SARS-associated coronavirus vaccine in monkeys", "authors": [{"first": "W", "middle": [], "last": "Gao", "suffix": ""}, {"first": "A", "middle": [], "last": "Tamin", "suffix": ""}, {"first": "A", "middle": [], "last": "Soloff", "suffix": ""}], "year": null, "venue": "Lancet", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "A DNA vaccine induces SARS coronavirus neutralization and", "authors": [{"first": "Z", "middle": ["Y"], "last": "Yang", "suffix": ""}, {"first": "W", "middle": ["P"], "last": "Kong", "suffix": ""}, {"first": "Y", "middle": [], "last": "Huang", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Angiotensin-converting enzyme 2 is a functional receptor for the SARS respiratory syndrome", "authors": [{"first": "W", "middle": [], "last": "Li", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Moore", "suffix": ""}, {"first": "N", "middle": [], "last": "Vasilieva", "suffix": ""}], "year": 2003, "venue": "N Engl J Med", "volume": "361", "issn": "", "pages": "1967--76", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "The severe acute respiratory syndrome", "authors": [{"first": "J", "middle": ["S"], "last": "Peiris", "suffix": ""}, {"first": "K", "middle": ["Y"], "last": "Yuen", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Osterhaus", "suffix": ""}, {"first": "K", "middle": [], "last": "Stohr", "suffix": ""}], "year": 2003, "venue": "N Engl J Med", "volume": "349", "issn": "", "pages": "2431--2472", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "using adenovirus vector", "authors": [], "year": 1997, "venue": "Cancer Res", "volume": "57", "issn": "", "pages": "1335--1378", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "T hybrid cells secreting immunoregulatory molecules", "authors": [], "year": 1981, "venue": "Proc Natl Acad Sci U S A", "volume": "78", "issn": "", "pages": "7717--7738", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "epithelial cell line from the adult H-2K(b)tsA58 transgenic mouse", "authors": [], "year": 2003, "venue": "In Vitro Cell Dev Biol Anim", "volume": "36", "issn": "", "pages": "1895--1901", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "protective immunity in mice", "authors": [], "year": 2004, "venue": "Nature", "volume": "428", "issn": "", "pages": "561--565", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "This study was also supported by a Health T cells in rhesus monkeys. SARS S DNA vaccines elicit neutralizing antibody responses that generate protective immunity in a mouse model (8). However, its immunogenicity inhumans has yet to be established. Therefore, it is very important to evaluate the efficacy of SARS DNA vaccines in SCID-PBL/hu mice", "authors": [{"first": "", "middle": [], "last": "Culture", "suffix": ""}, {"first": "", "middle": [], "last": "Sports", "suffix": ""}, {"first": "", "middle": [], "last": "Science", "suffix": ""}, {"first": "Japan", "middle": [], "last": "Technology", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "vaccinated with SARS CoV (N) DNA or (M) DNA using pcDNA 3.1(+) plasmid vector showed T-cell cells (T7) transfected with SARS (N) or (M) DNA, respectively. 562 immune responses (CTL induction and proliferation) against type II alveolar epithelial To determine whether these DNA vaccines could induce T-cell immune responses in humans as well as in mice, SCID-PBL/hu mice were immunized with these DNA vaccines. PBL from healthy human volunteers were administered i.p. into IL-2 receptor -chaindisrupted NOD-SCID mice [IL-2R(-/-) NOD-SCID]. SCID-PBL/hu mice thus constructed can be used to analyze the human immune response in vivo. The SCID-PBL/hu mice were immunized with SARS (N) DNA or (M) DNA and analyzed for a human T-cell immune response. The M DNA vaccine enhanced CTL activity and proliferation in the presence of M peptide in SCID-PBL/hu mice. Furthermore, the SARS N DNA vaccine induced CTL blast cells) and proliferation of spleen cells in SCID-PBL/hu mice. These results, demonstrate that SARS M and N DNA vaccines induced human CTL and human T-cell proliferative responses.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "CoV by SARS (N) DNA and SARS (M) DNA vaccine: Spleen cells from C57BL/6 mice immunized with SARS-S, -M, -N or -E DNA vaccine were cultured with syngeneic T7 lung cells transfected with S, M, N, or E cDNA. pcDNA 3.1(+) SARS (N) DNA vaccine induced significantly CTL activity (IFN-production) against N cDNA transfected T7 cells. Similarly, SARS M DNA vaccine induced SARS antigen M-specific CTL against T7 cells transfected with SARS M DNA. splenic T cells stimulated by co-culture either with T7 cells transfected with M DNA or SARS M peptide (TW1 M102-116) was strongly augmented by M DNA vaccine (data not shown). SARS N DNA vaccine also induced proliferation of splenic T cells in the presence of recombinant N protein as well as N DNA-transfected T7 cells. Thus, both SARS N 563 immunization with SARS (M) DNA and SARS (N) DNA vaccine: The proliferation of", "latex": null, "type": "figure"}, "FIGREF2": {"text": "OKADA ET AL. DNA vaccine and M DNA vaccine were shown to induce T-cell immune responses against Induction of neutralizing antibodies against SARS-CoV by immunization with SARS(S) DNA vaccine: The production of neutralizing antibodies against SARS CoV using Vero E6 cells infected with SARS CoV was observed in the serum from BALB/c mice Table 1. Induction of neutralizing antibody against SARS coronavirus by SARS (S) DNA vaccination of BALB/c mice. SARS M DNA and N DNA vaccines induced human T-cell immune responses (CTL and proliferation) and the production of neutralizing antibodies against SARS-CoV in SCID-PBL/hu model: The M DNA vaccine enhanced CTL activity and proliferation in the presence of M peptide in SCID-PBL/hu mice. Furthermore, the SARS N DNA vaccine autologous B blast cells) and proliferation of spleen cells in SCID-PBL/hu mice (Fig. 1). From these results, it was demonstrated that SARS M DNA vaccine and N DNA vaccine induced human CTL and human T-cell proliferative responses. Furthermore, human neutralizing antibodies were induced in SCID-PBL/hu mice vaccinated with SARS S and We have demonstrated that SARS (M) DNA and (N) DNA vaccines induce the relevant SARS-CoV antigens. (Table 1). immunized with S DNA vaccine in the presence of adjuvants (MPL+TDM+ALUM) M DNA (Table 2). induced CTL activity (IFN production by recombinant N protein or N protein-pulsed Im m u n iza tio n w ith A d ju v an t N eu tra lizin g a n tib od y A g ain st S A R S C o ron a V iru s IL -2 R g -ch a in (-/-) N O D -S C ID P B L /h u m ic e IL -2 R g -ch a in (-/-) N O D -S C ID P B L /VACCINES AND IMMUNOTHERAPY AGAINST SARS CORONA VIRUS SARS (N) DNA vaccine induces in vivo human CTL against SARS CoV in the SCID-PBL/hu human immune systems. 4x10 7 PBL from healthy human volunteers were administered i.p. into IL-2R (-/-) NOD-SCID. 1x10 5 spleen cells from SCID-PBL/hu were cultured with 10 \u00b5g of recombinant SARS (N) protein for 72hr.", "latex": null, "type": "figure"}, "FIGREF3": {"text": "50 \u00b5g of SARS (S) DNA was immunized three times into SCID mice (IL-2 Receptor -chain-disrupted NOD SCID) at the interval of 7 days. 565 systems using SCID-PBL/hu. Gao et al. showed that an adenovirus-based SARS DNA vaccine encoding S1 polypeptide was capable of inducing neutralizing antibody, virus-specific immune responses (CTL and T-cell proliferation) in the mouse system 6 induced SARS-CoV-specific CTL and T-cell proliferation in vivo human immune type II lung alveolar T-cell lines to present antigen These DNA vaccines .", "latex": null, "type": "figure"}, "TABREF0": {"text": "Induction of human neutralizing antibody against SARS coronavirus in SCID PBL/hu mice by SARS DNA vaccinations.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>M ic e\n</td><td>Im m u n iza t io n </td><td>A d ju v an t </td><td>N e u tra liz in g a n t ib od y\n</td></tr><tr><td>w ith\n</td><td>\u00a0</td><td>A g a in st S A R S C o ro n a V iru s\n</td></tr><tr><td>IL -2 R g -ch a in (- /- ) N O D -S C ID P B L /h u m ic e\n</td><td>S A R S T W 1 -S </td><td>A d en o v iru s v ec to r/\nIL -6 D N A + IL -6 R D N A + g p 1 3 0 D N A\n</td><td>+\n</td></tr><tr><td>S A R S (S ) D N A\n</td><td>+\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>M P L\n</td><td>\u00a0</td></tr><tr><td>IL -2 R g -ch a in (- /- )\n</td><td>S A R S (M ) D N A\n</td><td>A d e n o v iru s v e cto r/\n</td><td>\u00a0</td></tr><tr><td>N O D -S C ID P B L /h u m ic e\n</td><td>\u00a0</td><td>IL -6 D N A + IL -6 R D N A + g p 1 3 0 D N A\n</td><td>+\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>- </td><td>-\n</td></tr></table></body></html>"}}, "back_matter": []}